Nyumbani › Limfoma › Massachusetts › Boston
Majaribio ya kliniki ya Limfoma katika Boston, MA
Masomo 33 ya Limfoma yanatafuta washiriki katika vituo vya Boston na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
InaajiriHatua 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
InaajiriHatua 2
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Inaajiri
- Mass General Hospital, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Inaajiri
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
InaajiriHatua 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
InaajiriHatua 2
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
InaajiriHatua 1/2
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
InaajiriHatua 1/2
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
InaajiriHatua 3
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
InaajiriHatua 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
InaajiriHatua 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
InaajiriHatua 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
InaajiriHatua 2
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
InaajiriHatua 1/2
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
InaajiriHatua 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
InaajiriUtafiti wa uchunguzi
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
Inaajiri
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Inaajiri
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
InaajiriHatua 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Inaajiri
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
InaajiriHatua 2
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
InaajiriHatua 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
InaajiriHatua 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Inaajiri
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
InaajiriHatua 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
InaajiriHatua 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
InaajiriHatua 2
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
Inaajiri
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Majaribio ya Limfoma katika miji mingine
- Houston, TXUtafiti 34
- New York City, NYUtafiti 33
- Washington, DCUtafiti 23
- Baldwin Park, CAUtafiti 21
- Chicago, ILUtafiti 20
- Durham, NCUtafiti 17
- St. Louis, MOUtafiti 15
- Philadelphia, PAUtafiti 15
- Cleveland, OHUtafiti 14
- Edison, NJUtafiti 12
- Atlanta, GAUtafiti 12
- Seattle, WAUtafiti 12
Masomo mengine katika Boston
- Saratani ya MatitiUtafiti 111
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 90
- Saratani (aina zote)Utafiti 86
- Kansari ya kolorektaliUtafiti 63
- Saratani ya MetastasiUtafiti 63
- Saratan ya MapafuUtafiti 62
- Kansari ya MayaiUtafiti 61
- Saratani ya ProstateUtafiti 59
- HuzuniUtafiti 52
- Saratani ya EndometrialUtafiti 50
- Kushindwa kwa MoyoUtafiti 44
- Leukemia ya Myeloid ya GhaflaUtafiti 44
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.